80%Confidence
0Views
FDASource
2026-04-09Date
Summary
Macleods Pharma's Class II recall for subpotent Levothyroxine Sodium tablets suggests manufacturing quality failures, potentially affecting patient safety and trust in this widely used thyroid medication. This could lead to market share loss and increased regulatory oversight for the company, especially as it involves a high-volume product.
Actionable: Evaluate competitive opportunities in the thyroid medication market as Macleods addresses this recall.
AI Confidence: 80%
Data Points
firmMACLEODS PHARMA USA, INC
classificationClass II
statusOngoing
distributionNationwide
productLevothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Princeton, NJ, Manufactured by: M
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now